Kos Biotechnology Partners Makes Inaugural Investment in Epikast's Technology-Enabled Pharma Services Platform
核心洞察
Kos Biotechnology Partners (搜索) completed its first investment by leading a financing round for Epikast (搜索), a technology-enabled biopharmaceutical services company.
Epikast (搜索) provides remote commercial, medical, and patient support services to global pharma companies through its Greece-based operational hub and proprietary technology platform.
The investment will enhance Epikast (搜索)'s technology capabilities and scale its specialized service teams to address inefficiencies in biopharma-healthcare provider engagement.
Kos Biotechnology Partners (搜索), a global life sciences investment firm, has completed its inaugural investment by leading a financing round in Epikast (搜索), a technology-enabled biopharmaceutical services company. The transaction marks the first deployment of capital from Kos' inaugural fund, which focuses on seeding and scaling high-impact life sciences platforms across various investment stages.
The financing round included significant participation from both new and existing investors, with Kos taking the lead investor position. As part of the investment, Alex Tzoukas (搜索), Managing Partner and Co-Founder at Kos, will join Epikast (搜索)'s Board of Directors.
Technology-Enabled Service Model
Epikast (搜索) operates a differentiated business model that bridges high-level medical expertise with cost-efficient operations. The company leverages its Greece-based operational hub to deliver remote commercial, medical, market access, and patient support services to global biopharmaceutical clients. By combining highly trained medical professionals with a proprietary technology stack, Epikast provides high-quality engagement and data-driven insights at an optimized cost structure.
The company currently partners with several global top 10 pharmaceutical companies and smaller biotechnology companies as they commercialize their products in the US and Europe. Epikast (搜索)'s comprehensive suite of services addresses what investors describe as clear inefficiencies in how biopharma companies engage with healthcare providers and patients.
Strategic Investment Rationale
"Epikast (搜索) represents an exciting investment for our new fund," said Alex Tzoukas (搜索), Managing Partner and Co-Founder of Kos Biotechnology Partners (搜索). "The company has developed a differentiated, tech-enabled pharma services model that addresses a clear inefficiency in how biopharma companies engage with healthcare providers and patients. We are pleased to lead this round and support the company as it scales."
The capital infusion will be directed toward enhancing Epikast (搜索)'s proprietary technology platform and scaling its specialized service teams. This investment aligns with Kos' strategy of partnering with experienced management teams to build enduring products, services, and platforms through strategic capital and operational expertise.
Leadership and Governance
Epikast (搜索) was co-founded by Dr. Stelios Papadopoulos (搜索), a recognized biotechnology industry luminary who serves as the company's Chairman. Dr. Vangelis Vergetis (搜索) leads the organization as CEO from the company's New York headquarters.
"We are pleased to welcome Kos Biotechnology Partners (搜索) as lead investor in this round," said Dr. Papadopoulos. "Kos brings deep sector expertise and a strong connection to both the US and Greek innovation ecosystems, which aligns well with Epikast (搜索)'s operating model. Alex's addition to the board adds valuable perspective as we enter the next phase of growth."
Dr. Simos Simeonidis (搜索), Managing Partner and Co-Founder of Kos Biotechnology Partners (搜索), emphasized the strategic value of the partnership: "We are pleased to partner with Stelios and his team at Epikast (搜索) with the first investment from our fund. Alex's deep background as a life sciences investor, investment banker, and operator will further enhance the strong expertise already present on Epikast's Board."
Growth Trajectory
The financing comes as Epikast (搜索) experiences strong momentum in the market. CEO Dr. Vergetis noted the company's focus on strategic partnerships: "This financing reinforces Epikast's strong momentum. We place a premium on partnering with individuals who bring deep expertise and strong judgment. Alex Tzoukas (搜索), Simos Simeonidis, and Nikos Kostaras exemplify that and will be valuable partners as we advance our next phase."
Kos Biotechnology Partners (搜索) was founded in 2025 by Dr. Simos Simeonidis (搜索) and Alex Tzoukas (搜索), with a mandate to identify, support, and scale innovative opportunities in the life sciences sector. The firm's inaugural fund targets a broad range of investment stages and maintains a long-term perspective on value creation in the biotechnology and pharmaceutical services sectors.